Topical therapy with negative allosteric modulators of the calcium-sensing receptor (calcilytics) for the management of asthma: the beginning of a new era?

Daniela Riccardi; Jeremy P T Ward; Polina L Yarova; Luke J Janssen; Tak Hong Lee; Sun Ying; Chris J Corrigan

doi:10.1183/13993003.02103-2021

Topical therapy with negative allosteric modulators of the calcium-sensing receptor (calcilytics) for the management of asthma: the beginning of a new era?

Eur Respir J. 2022 Aug 10;60(2):2102103. doi: 10.1183/13993003.02103-2021. Print 2022 Aug.

Authors

Daniela Riccardi¹, Jeremy P T Ward², Polina L Yarova³, Luke J Janssen⁴, Tak Hong Lee^{2

5}, Sun Ying⁶, Chris J Corrigan⁷

Affiliations

¹ Cardiff School of Biosciences, University of Cardiff, Cardiff, UK.
² Faculty of Life Sciences and Medicine and Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, London, UK.
³ Translational and Clinical Research Institute, School of Medical Sciences, Newcastle University, Newcastle, UK.
⁴ Dept of Medicine, McMaster University, Hamilton, ON, Canada.
⁵ Hong Kong Sanatorium and Hospital, Hong Kong, China.
⁶ Dept of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.
⁷ Faculty of Life Sciences and Medicine and Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, London, UK chris.corrigan@kcl.ac.uk.

PMID: 35058244
DOI: 10.1183/13993003.02103-2021

Abstract

In this review article we present the evidence to date supporting the role of the calcium-sensing receptor (CaSR) as a key, pluripotential molecular trigger for asthma and speculate on the likely benefits of topical therapy of asthma with negative allosteric modulators of the CaSR: calcilytics.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Asthma* / drug therapy
Calcium
Humans
Receptors, Calcium-Sensing*

Substances

Receptors, Calcium-Sensing
Calcium